Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi PharmaphorumThe FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.NeuroscienceRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) Pharmaphorum The FDA has cleared Eisai and Biogen’s Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellares and Sonoma partner to automate cell therapy manufacturingNext: Novartis and Chai Discovery collaborate on antibody identification Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
